Quick Answer
Cardiol Therapeutics Inc. reported Research And Development Expense of $14.22 million for the year ending 2023.
- Cardiol Therapeutics Inc. showed a decrease of -25.0% in Research And Development Expense from 2022 to 2023.
- This data is from Cardiol Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on April 1, 2024.
- XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2020 to 2023), Cardiol Therapeutics Inc.'s Research And Development Expense has grown by 34.2%.
- Historical annual values: Fiscal year 2023: $14.22 million | Fiscal year 2022: $18.96 million | Fiscal year 2021: $10.87 million | Fiscal year 2020: $10.60 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: